These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23023518)

  • 1. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors.
    Elsayed MS; El-Araby ME; Serya RT; Abouzid KA
    Arzneimittelforschung; 2012 Dec; 62(12):554-60. PubMed ID: 23023518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
    Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors.
    Furdas SD; Shekfeh S; Bissinger EM; Wagner JM; Schlimme S; Valkov V; Hendzel M; Jung M; Sippl W
    Bioorg Med Chem; 2011 Jun; 19(12):3678-89. PubMed ID: 21353783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational approach to the identification of novel Aurora-A inhibitors.
    Morshed MN; Cho YS; Seo SH; Han KC; Yang EG; Pae AN
    Bioorg Med Chem; 2011 Jan; 19(2):907-16. PubMed ID: 21194953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
    Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving VEGFR-2 docking-based screening by pharmacophore postfiltering and similarity search postprocessing.
    Planesas JM; Claramunt RM; Teixidó J; Borrell JI; Pérez-Nueno VI
    J Chem Inf Model; 2011 Apr; 51(4):777-87. PubMed ID: 21417262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
    Li S; Sun X; Zhao H; Tang Y; Lan M
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4004-9. PubMed ID: 22595177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
    Tripathy R; Reiboldt A; Messina PA; Iqbal M; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Robinson C; Chang H; Ruggeri BA; Mallamo JP
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2158-62. PubMed ID: 16460933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
    Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
    Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
    Chen Z; Tian G; Wang Z; Jiang H; Shen J; Zhu W
    J Chem Inf Model; 2010 Apr; 50(4):615-25. PubMed ID: 20353193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
    Luan X; Gao C; Zhang N; Chen Y; Sun Q; Tan C; Liu H; Jin Y; Jiang Y
    Bioorg Med Chem; 2011 Jun; 19(11):3312-9. PubMed ID: 21576023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
    Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
    Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
    Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
    Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Garofalo A; Farce A; Ravez S; Lemoine A; Six P; Chavatte P; Goossens L; Depreux P
    J Med Chem; 2012 Feb; 55(3):1189-204. PubMed ID: 22229669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach.
    Zhang L; Wang X; Feng J; Jia Y; Xu F; Xu W
    Chem Biol Drug Des; 2012 Dec; 80(6):893-901. PubMed ID: 22913881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.